学院
大会日程

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Pfizer, Genzyme/Sanofi, Stiefel/GSK, Celgene, Aclaris Therapeutics, Dermira, Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics, Dermavant, Tevido BioDevices, EMD Serono Consultant – Pfizer, Abbvie, Genzyme/Sanofi, Aclaris Therapeutics, Janssen, TeVido BioDevices, EMD Serono, Rheos Medicines, Sun Pharmaceuticals, NIRA Biosciences, Vimela Therapeutics, KliRNA Therapeutics, Dermavant, Temprian Therapeutics, Almirall, Boston Pharma, Cogen Therapeutics, Admirx, Avita, Incyte Corp, LEO Pharma, 3rd Rock Ventures Equity – TeVido Biodevices, Rheos Medicines, Incyte Corp (auremolimab), NIRA Biosciences, Aldena Therapeutics, Vimela Therapeutics, KliRNA Therapeutics Founder – Villaris Therapeutics, Inc, NIRA Biosciences, Aldena Therapeutics, Vimela Therapeutics, KliRNA Therapeutics

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: In this lecture, we aim to explore the potential of teledermatology in enhancing accessibility to dermatology care. Our primary objective is to highlight the practical advantages of store and forward teledermatology, emphasizing its impact on improving the diagnosis and management of skin conditions. By presenting a real-life case of vitiligo, we intend to illustrate how this innovative approach can benefit patients and healthcare providers alike, ultimately leading to improved healthcare outcomes and increased access to dermatological services.

Introduction: Access to dermatology care remains a significant challenge in many regions due to factors such as geographical barriers, long wait times, and a shortage of dermatologists. Teledermatology, specifically the store and forward method, offers a promising solution to address these issues. This lecture introduces the concept of teledermatology and its various modalities, emphasizing the convenience, cost-effectiveness, and potential to reach underserved populations. Furthermore, it sets the stage for a compelling case study focusing on a patient with vitiligo.

Materials / method: The patient's medical history, clinical photographs, and relevant data were collected and transmitted to a remote dermatologist, who provided a diagnosis and treatment plan. This teledermatology approach allows for asynchronous consultation, bypassing the need for in-person appointments and reducing waiting times for specialized care.

Results: The presentation will showcase the results of the vitiligo case study, emphasizing the successful diagnosis and treatment facilitated through store and forward teledermatology. We will discuss the patient's experience, including the convenience of remote consultations and the timely delivery of care. Furthermore, we will highlight the broader implications of this case in the context of improving access to dermatology care for a diverse range of skin conditions. The lecture will conclude with a discussion of the wider implications of teledermatology in expanding access to dermatological service

Conclusion: As we conclude, it is clear that teledermatology is not only a game-changer for dermatology care but also a model for the future of healthcare accessibility. The success of this approach in improving patient outcomes, reducing healthcare costs, and increasing access to specialized care should inspire healthcare systems to further embrace telemedicine solutions.

However, it is essential to acknowledge that while store and forward teledermatology offers many advantages, it is not a one-size-fits-all solution. Challenges such as patient privacy, technology limitations, and the need for appropria

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Founder of FORMEL Skin

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。